Adirondack Trust Co. Cuts Stake in Danaher Co. (NYSE:DHR)

Adirondack Trust Co. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 1.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 4,443 shares of the conglomerate’s stock after selling 47 shares during the quarter. Adirondack Trust Co.’s holdings in Danaher were worth $1,125,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DHR. HighPoint Advisor Group LLC purchased a new stake in shares of Danaher during the 4th quarter valued at about $2,614,000. Grayhawk Investment Strategies Inc. boosted its holdings in shares of Danaher by 341.9% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 190 shares of the conglomerate’s stock worth $44,000 after buying an additional 147 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Danaher by 8.8% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 11,434 shares of the conglomerate’s stock worth $2,648,000 after buying an additional 926 shares during the last quarter. MONECO Advisors LLC boosted its holdings in shares of Danaher by 14.5% in the fourth quarter. MONECO Advisors LLC now owns 986 shares of the conglomerate’s stock worth $228,000 after buying an additional 125 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in shares of Danaher in the fourth quarter worth approximately $290,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Robert W. Baird raised their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. TD Cowen raised their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Jefferies Financial Group assumed coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Citigroup raised their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Monday. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $269.29.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 148,783 shares of company stock valued at $37,536,717. 10.90% of the stock is currently owned by company insiders.

Danaher Trading Up 0.8 %

NYSE DHR traded up $2.11 on Tuesday, hitting $256.24. 1,025,292 shares of the stock were exchanged, compared to its average volume of 2,761,135. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock has a fifty day moving average price of $253.68 and a two-hundred day moving average price of $244.68. The firm has a market capitalization of $189.79 billion, a P/E ratio of 43.07, a P/E/G ratio of 3.90 and a beta of 0.85. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $269.11.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.36 earnings per share. Research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.